English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists

Yamazaki, T., Hannani, D., Poirier-Colame, V., Ladoire, S., Locher, C., Sistigu, A., et al. (2013). Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death and Differentiation, 21, 69-78.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Yamazaki, T., Author
Hannani, D., Author
Poirier-Colame, V., Author
Ladoire, S., Author
Locher, C., Author
Sistigu, A., Author
Prada, N., Author
Adjemian, S., Author
Catani, J. P. P., Author
Freudenberg, M.1, Author           
Galanos, C.2, Author           
André, F., Author
Kroemer, G., Author
Zitvogel, L., Author
Affiliations:
1Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society, ou_2243647              
2Emeritus Group: Cellular Immunology, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society, ou_2243649              

Content

show
hide
Free keywords: TLR4; immunogenic cell death; chemotherapy; Dendrophilin; cancer
 Abstract: Immunogenic cell death induced by anticancer chemotherapy is characterized by a series of molecular hallmarks that include the exodus of high-mobility group box 1 protein (HMGB1) from dying cells. HMGB1 is a nuclear nonhistone chromatin-binding protein. It is secreted at the late stages of cellular demise and engages Toll-like receptor4 (TLR4) on dendritic cells (DCs) to accelerate the processing of phagocytic cargo in the DC and to facilitate antigen presentation by DC to T cells. The absence of HMGB1 expression by dying tumor cells exposed to anthracyclines or oxaliplatin compromises DC-dependent T-cell priming by tumor-associated antigens. Here, we show that transplantable tumors exhibiting weak expression of nuclear HMGB1 respond to chemotherapy more effectively if the treatment is combined with the local or systemic administration of a highly purified and physiochemically defined and standardized lipopolysaccharide solution, which acts as a high-potency and exclusive TLR4 agonist, called Dendrophilin (DEN). The synergistic antitumor effects mediated by the combination of chemotherapy and immunotherapy relied upon the presence of the MyD88 (myeloid differentiation primary response gene) adapter of TLR4 (but not that of the TIR-domain-containing adapter-inducing interferon-β adapter), in line with the well-characterized action of DEN on the MyD88 signaling pathway. DEN and anthracyclines synergized to induce intratumoral accumulation of interferon-γ-producing CD4+ and CD8+ T lymphocytes. Moreover, DEN could restore the immunogenicity of dying tumor cells from which HMGB1 had been depleted by RNA interference. These findings underscore the potential clinical utility of combination regimens involving immunogenic chemotherapy and certain TLR4 agonists in advanced HMGB1-deficient cancers.

Details

show
hide
Language(s): eng - English
 Dates: 2013
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: eDoc: 677790
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Cell Death and Differentiation
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 21 Sequence Number: - Start / End Page: 69 - 78 Identifier: -